Advertisement

The Use of Indirect Indicator Systems to Detect Mutagenic Activity in Human Subjects and Experimental Animals

  • M. S. Legator
  • S. Zimmering
  • T. H. Connor
Part of the Chemical Mutagens book series

Abstract

Whereas exposure of human beings to potential mutagens is very likely increasing as a result of pollution from chemicals and chemical by-products used in or generated by agricultural and industrial operations as well as by drugs used for therapeutic purposes in medicine, evaluation of the genetic hazards associated with such exposure poses problems not amenable to simple solutions. Complete assessment of the mutagenic effect of a given chemical in human beings would require in the least not only considerable information on the genetic effects of the chemical and its possible interactions with other substances, but also information on the magnitude of health resources necessary to respond to such mutations. On the other hand, first steps can be taken in the identification of a potentially genetically hazardous compound by means of well-established detection procedures (and, in the future, by those under development and holding promise of success) devised and refined by many workers m a wide variety of organisms ranging from bacteria to subhuman mammals to man.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B. Commoner, A. J. Vithayathil, and J. I. Henry, Detection of metabolic carcinogen intermediates in urine of carcinogen-fed rats by means of bacterial mutagenesis. Nature 249, 850–852 (1974).PubMedCrossRefGoogle Scholar
  2. 2.
    W. Durston and B. N. Ames, A sample method for the detection of mutagens in urine: Studies with the carcinogens 2-Acetylaminofluorine, Proc. Nat. Acad. Sci. USA 71, 737–741 (1974).PubMedCrossRefGoogle Scholar
  3. 3.
    M. S. Legator, M. Stoeckel, and T. H. Connor, Techniques for isolating mutagenic substances from urine and blood of treated mammals using histidine auxotrophs of S. typhimurium as the indicator organisms, Mutat. Res. 26, 456 (1974).Google Scholar
  4. 4.
    M. G. Gabridge, A. DeNunzio, and M. S. Legator, Microbial mutagenicity of streptozotocin in animal-mediated assays. Nature 68, 221 (1969).Google Scholar
  5. 5.
    G. Krick, T. Connor, and S. R. Kaplan, Abstract No. 99, 39th Annual Meeting of the Aiperican Rheumatism Association Section of the Arthritis Foundation, June 4–6, 1975, New Orleans, LA.Google Scholar
  6. 6.
    D. Siebert, and U. Simon, Genetic activity of metabolites in the acitic fluid and in the urine of a human patient treated with cyclophosphamide: Induction of mitotic gene conversion in Saccharomyces Cerevisiae, Mutat. Res. 21, 257–262 (1973).PubMedCrossRefGoogle Scholar
  7. 7.
    D. Siebert, and U. Simon, Cyclophosphamide: Pilot study of genetically active metabolites in the urine of a treated human patient. Induction of mitotic gene conversions in yeast, Mutat. Res., 19, 65–72 (1973).PubMedCrossRefGoogle Scholar
  8. 8.
    D. Siebert, Induction of mitotic conversions in Saccharomyces Cerevisiae by lymph fluid and urine of cyclophosphamide-treated rats and human patients, Mutat. Res. 21, 202 (1973).CrossRefGoogle Scholar
  9. 9.
    D. Siebert, A new method for testing genetically active metabolites: Urinary assay with cyclophosphamide (Endoxan, Cytoxan) andSaccharomyces Cerevisiae, Mutat. Res. 17, 307–314 (1973).PubMedCrossRefGoogle Scholar
  10. 10.
    D. R. Stoltz and C. T. Miller, Abstract No. Ac-11, Sixth Annual Meeting of the Environmental Mutagen Society, May 9–12, 1975, Miami Beach, Fla.Google Scholar
  11. 11.
    M. S. Legator, T. H. Connor, and M. Stoeckel, Detection of mutagenic activity of metronidazole and niridazole in body fluids of humans and mice with Satmonetta typhimurium. Science 188, 1118(1975).Google Scholar
  12. 12.
    T. H. Connor, M. Stoeckel, J. Evrard, and M. S. Legator, The contribution of metronidazole and two metabolites of treated humans and mice. Cancer Res., in press.Google Scholar
  13. 13.
    C. E. Voogd, J. J. Van Der Stel, and J. J. J. A. A. Jacobs, The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole, and ronidazole, Mutat. Res. 26, 483–490 (1974).PubMedCrossRefGoogle Scholar
  14. 14.
    M. Rustia and P. J. Shubick, J. Nat. Cancer Inst. 48, 721 (1972).PubMedGoogle Scholar
  15. 15.
    B. N. Ames, F. D. Lee, and W. E. Durston, An improved bacterial test system for the detection and classification of mutagens and carcinogens, Proc. Nat. Acad. Sci. USA 70, 782–786 (1973).PubMedCrossRefGoogle Scholar
  16. 16.
    B. N. Ames, W. E. Durston, E. Yamasaki, and F. D. Lee, Carcinogens are mutagens: A simple test combining liver homogenates for activation and bacteria for detection, Proc. Nat. Acad. Sci. USA 70, 2281–2285 (1973).PubMedCrossRefGoogle Scholar
  17. 17.
    J. E. Stambaugh, L. G. Feo, and R. W. Manthei, Pharmacol. Exp. Therap. 161(2), 373–381 (1968).Google Scholar
  18. 18.
    L. S. Browning, Recessive-lethal frequency in Drosophila after injection with intraperitoneal fluid from mice previously injected with methylsulfonate, EMS Newsl. 6, 8–9 (1972).Google Scholar
  19. 19.
    P. A. Gee, G. Sega, and W. R. Lee, Comparison of chemical assay with a tissue-mediated bio-assay for chemical mutagens, Mutat. Res. 16, 215–221 (1972).PubMedCrossRefGoogle Scholar
  20. 20.
    L. S. Browning, Mutagenicity of various chemicals and their metabolites in Drosophila, Genetics 74, S33 (1973).Google Scholar
  21. 21.
    E. Lewis and F. Bâcher, Method of feeding ethylmethane sulfonate (EMS) to Drosophila males,Drosophila Inf. Serv. 43/193 (1968).Google Scholar
  22. 22.
    D. Mendelson and F. Sobels, The inhibiting effect of caffeine on the material repair of radiation-induced chromosome breaks in Drosophila, Mutat. Res. 26, 123–128 (1974).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • M. S. Legator
    • 1
  • S. Zimmering
    • 2
  • T. H. Connor
    • 3
  1. 1.Department of Preventive Medicine and Community HealthUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Division of Biological and Medical SciencesBrown UniversityProvidenceUSA
  3. 3.The Department of Genetic ToxicologyThe Miriam HospitalProvidenceUSA

Personalised recommendations